Treatment of severe small airways disease in children with cystic fibrosis: Alternatives to corticosteroids

Pediatric Drugs

Volumn 4, Issue 6, 2002, Pages 381-389

  Jaffe, A ^a   Balfour Lynn, I M ^b  

^a GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^b ROYAL BROMPTON AND HAREFIELD NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; ANTIINFLAMMATORY AGENT; AZITHROMYCIN; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; BUDESONIDE; CLARITHROMYCIN; CORTICOSTEROID; CROMOGLYCATE DISODIUM; CYCLOSPORIN; DEXAMETHASONE; ERYTHROMYCIN; IBUPROFEN; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; IPRATROPIUM BROMIDE; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MACROLIDE; METHOTREXATE; MONTELUKAST; NONSTEROID ANTIINFLAMMATORY AGENT; PREDNISONE; SALBUTAMOL; SALMETEROL; TERBUTALINE; THEOPHYLLINE; TICARCILLIN; UNINDEXED DRUG; ZAFIRLUKAST;

ADOLESCENT; ANIMAL MODEL; ANTIINFLAMMATORY ACTIVITY; ASTHMA; BRONCHIOLITIS; BRONCHODILATATION; BRONCHOPULMONARY ASPERGILLOMA; BRONCHOSPASM; CHILD; CHILDHOOD DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; CYSTIC FIBROSIS; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG INDUCED DISEASE; GASTROESOPHAGEAL REFLUX; HUMAN; IMMUNOTHERAPY; LUNG DISEASE; NEPHROTOXICITY; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; SMALL AIRWAY DISEASE;

EID: 0036081002     PISSN: 11745878     EISSN: None     Source Type: Journal    
DOI: 10.2165/00128072-200204060-00005     Document Type: Review

References (91)

1. Respiratory system
2. The value of ultrafast computed tomography in the investigation of pediatric chest disease
3. Severe small airways disease resistant to medical treatment in a child with cystic fibrosis
4. Risks of alternate-day prednisone in patients with cystic fibrosis
5. Pathology of cystic fibrosis review of the literature and comparison with 146 autopsied cases
6. Early pulmonary inflammation in infants with cystic fibrosis
7. Lower respiratory infection and inflammation in infants with newly diagnosed cystic fibrosis
8. The protease-antiprotease battle in the cystic fibrosis lung
9. The apthology of cystic fibrosis
10. Small airways: A time to revisit
11. Resistance of central and peripheral airways measured by a retrograde catheter
12. Variability of pulmonary function tests in cystic fibrosis
13. Respiratory impedance and multibreath N2 washout in healthy, asthmatic, and cystic fibrosis subjects
14. Bronchodilators in cystic fibrosis
15. Bronchial vagal tone and responsiveness to histamine, exercise and bronchodilators in adult patients with cystic fibrosis
16. Effectiveness of bronchodilators in cystic fibrosis
17. Rise in total IgE as an indicator of allergic bronchopulmonary aspergillosis in cystic fibrosis
18. Effects of itraconazole therapy in allergic bronchopulmonary aspergillosis
19. Gastrointestinal and pancreatic disease in cystic fibrosis
20. Gastro-oesophageal reflux and childhood asthma: The acid test
21. Postural drainage and gastro-oesophageal reflux in infants with cystic fibrosis
22. Holding the baby: Head downwards positioning for physiotherapy does not cause gastro-oesophageal reflux
23. Epidemiological study of cystic fibrosis: Design and implementation of a prospective, multicenter, observational study of patients with cystic fibrosis in the US and Canada
24. International practice patterns by age and severity of lung disease in cystic fibrosis: Data from the epidemiological registry of cystic fibrosis (ERCF)
25. CF asthma: What is it and what do we do about it
26. Alternate-day prednisone reduces morbidity and improves pulmonary function in cystic fibrosis
27. Tracheal mucociliary transport in patients with cystic fibrosis and its stimulation by terbutaline
28. Patterns of medical practice in cystic fibrosis, part II: Use of therapies. Investigators and coordinators of the Epidemiologic Study of Cystic Fibrosis
29. The effects of albuterol on the lung function of hospitalized patients with cystic fibrosis
30. A placebo-controlled, double-blind trial of the long-term effects of albuterol administration in patients with cystic fibrosis
31. Short-term and long-term effects of albuterol aerosol therapy in cystic fibrosis: A preliminary report
32. Comparison of nebulized and intravenous terbutaline during exacerbations of pulmonary infection in patients with cystic fibrosis
33. Ambulatory long-term subcutaneous salbutamol infusion in chronic severe asthma
34. Children with difficult asthma: A practical approach
35. Subcutaneous terbutaline in children with chronic severe asthma
36. Short-term effects of regular salmeterol treatment on adult cystic fibrosis patients
37. Effects of standard and high doses of salmeterol on lung function of hospitalized patients with cystic fibrosis
38. The inhaled bronchodilators ipratropium bromide and metaproterenol in adults with CF
39. Acute bronchodilator response to a combination of beta-adrenergic and anticholinergic agents in patients with cystic fibrosis
40. Efficacy of salbutamol and ipratropium bromide in decreasing bronchial hyperreactivity in children with cystic fibrosis
41. Bronchodilatory effects of salbutamol, ipratropium bromide, and their combination: Double-blind, placebo-controlled crossover study in cystic fibrosis
42. Sodium cromoglycate-induced changes in the dose-response curve of inhaled methacholine in cystic fibrosis
43. A double-blind, randomized study of sodium cromoglycate versus placebo in patients with cystic fibrosis and bronchial hyperreactivity
44. Comparison of efficacy of salbutamol and sodium cromoglycate in the prevention of ticarcillin-induced bronchoconstriction
45. Intravenous aminophylline in patients with cystic fibrosis: Pharmacokinetics and effect on pulmonary function
46. Airway obstruction and airway wall instability in cystic fibrosis: The isolated and combined effect of theophylline and sympathomimetics
47. Bronchodilation from intravenous theophylline in patients with cystic fibrosis: Results of a blinded placebo-controlled crossover clinical trial
48. Effect of theophylline on lung function tests, sleep quality, and nighttime SaO2 in children with cystic fibrosis
49. Effects of methylxanthines on airway mucociliary function
50. Paradoxic effect of ibuprofen on neutrophil accumulation in pulmonary and cutaneous inflammation
51. Effect of high-dose ibuprofen in patients with cystic fibrosis
52. Renal failure and vestibular toxicity in an adolescent with cystic fibrosis receiving gentamicin and standard-dose ibuprofen
53. Pharmacokinetics of ibuprofen in patients with cystic fibrosis
54. Corticosteroids and ibuprofen in cystic fibrosis
55. The use of anti-inflammatory medications in cystic fibrosis: Trends and physician attitudes
56. Diffuse panbronchiolitis and cystic fibrosis: East meets west
57. Diffuse panbronchiolitis in an Asian immigrant
58. Long-term low-dose administration of erythromycin to patients with diffuse panbronchiolitis
59. Interleukin 1 beta, tumor necrosis factor alpha, and interleukin 8 in bronchoalveolar lavage fluid of patients with diffuse panbronchiolitis: A potential mechanism of macrolide therapy
60. Diffuse panbronchiolitis: Efficacy of low-dose erythromycin
61. Long-term azithromycin may improve lung function in children with cystic fibrosis
62. Effect of clarithromycin on airway obstruction and inflammatory markers in induced sputum in cystic fibrosis: A pilot study
63. Anti-inflammatory effects of macrolides in lung disease
64. Erythromycin and clarithromycin attenuate cytokine-induced endothelin-1 expression in human bronchial epithelial cells
65. Contractile activity of three endothelins (ET-1, ET-2 and ET-3) on the human isolated bronchus
66. Effects of macrolide antibiotics on neurally mediated contraction of human isolated bronchus
67. Methylprednisolone and troleandomycin in treatment of steroid-dependent asthmatic children
68. Effect of low-dose troleandomycin on glucocorticoid pharmacokinetics and airway hyperresponsiveness in severely asthmatic children
69. Efficacy and safety of low-dose troleandomycin therapy in children with severe, steroid-requiring asthma
70. Benefits and complications of troleandomycin (TAO) in young children with steroid-dependent asthma
71. Roxithromycin reduces the degree of bronchial hyperresponsiveness in children with asthma
72. A prospective double-blind randomised placebo controlled cross over trial of long-term azithromycin in children
73. An open-label study of high-dose intravenous immunoglobulin in severe childhood asthma
74. Slight steroid-sparing effect of intravenous immunoglobulin in children and adolescents with moderately severe bronchial asthma
75. Mechanisms of glucocorticoid reduction in asthmatic subjects treated with intravenous immunoglobulin
76. Effect of intravenous immunoglobulin on steroid consumption in patients with severe asthma: A double-blind, placebo-controlled, randomized trial
77. Intravenous immunoglobulin inhibits IgE production in human B lymphocytes
78. Intravenous immune globulin treatment of pulmonary exacerbations in cystic fibrosis
79. Proteins of the cystic fibrosis respiratory tract: Fragmented immunoglobulin G opsonic antibody causing defective opsonophagocytosis
80. Pseudomonas hyperimmune globulin passive immunotherapy for pulmonary exacerbations in cystic fibrosis
81. Intravenous immunoglobulin (IVIG) for severe lung disease in children with CF
82. The use of cyclosporin in corticosteroid dependent asthma
83. Use of cyclosporin A as a steroid sparing agent in cystic fibrosis
84. Sputum cysteinyl-leukotriene levels correlate with the severity of pulmonary disease in children with cystic fibrosis
85. Eicosapentaenoic acid in cystic fibrosis: Evidence of a pathogenetic role for leukotriene B4
86. Leukotriene B4 markedly elevated in the epithelial lining fluid of patients with cystic fibrosis
87. Montelukast sodium in cystic fibrosis